
AzurRx BioPharma, Inc. Market Cap 2011-2026 | AZRX
As of March 05, 2026 AzurRx BioPharma, Inc. has a market cap of $ 34.4 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap AzurRx BioPharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 40.9 M | 20.4 M | 31.3 M | 37 M | 29.3 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 40.9 M | 20.4 M | 31.8 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
3.78 B | $ 16.45 | 0.43 % | $ 3.92 B | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
962 M | $ 3.64 | -1.89 % | $ 1.09 B | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
4.09 M | $ 0.83 | 4.23 % | $ 4.53 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 8.4 | -1.81 % | $ 1.39 B | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
1.2 B | $ 76.75 | 0.85 % | $ 1.48 B | ||
|
Apellis Pharmaceuticals
APLS
|
2.77 B | $ 19.93 | -1.14 % | $ 2.51 B | ||
|
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
98 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
8.67 B | $ 163.82 | -0.14 % | $ 8.15 B | ||
|
BridgeBio Pharma
BBIO
|
13.1 B | $ 66.98 | 3.8 % | $ 12.8 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.88 | 2.51 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 60.75 | 3.79 % | $ 11.7 B | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
215 K | $ 3.24 | 1.73 % | $ 1.16 M | ||
|
Cabaletta Bio
CABA
|
20.5 M | $ 3.41 | 4.77 % | $ 3.98 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
155 M | $ 25.71 | -0.5 % | $ 688 M | ||
|
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 28.49 | 0.04 % | $ 1.65 B | ||
|
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | ||
|
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M |